Core Viewpoint - Tivity Health has appointed Natasha Deckmann, M.D., as the new Chief Executive Officer to drive growth and strategic priorities for the organization [1][4]. Company Leadership - Natasha Deckmann has over 20 years of leadership experience in healthcare services, health systems, financial services, and consulting, having joined Tivity Health in 2024 as Chief Transformation Officer [3][5]. - Caroline Khalil, the current President and Chief Operating Officer, will collaborate with Ms. Deckmann to leverage their leadership strengths for the benefit of Tivity Health's members and clients [7][8]. - Brian Kane has been appointed as Executive Chairman of the Board, bringing over 25 years of experience in healthcare services and capital markets, including leadership roles at Aetna and Humana [9][10]. Strategic Focus - As CEO, Ms. Deckmann will focus on engaging with customers and expanding Tivity Health's product portfolio to achieve significant growth in both top and bottom lines [4]. - The leadership team aims to enhance the value delivered to clients, partners, and members while continuing to support Tivity Health's mission of promoting healthier and more active lifestyles [6][11].

SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene as well as certain of Centene’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene cl ...

Core Viewpoint - Astrana Health, Inc. (ASTH) shows significant upside potential with a mean price target of $49.56, indicating a 97.3% increase from the current price of $25.12 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from a low of $36.00 to a high of $70.00, with a standard deviation of $12.39, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 43.3%, while the highest suggests a 178.7% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ASTH's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two estimates have been revised upward, leading to a 46.4% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ASTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future potential through projected earnings and sales growth [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines the three Style Scores to highlight stocks with attractive value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [7] - There are typically over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down their choices [8] - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: HealthEquity (HQY) - HealthEquity, based in Draper, UT, provides integrated healthcare account management solutions and is rated 2 (Buy) with a VGM Score of B [11] - The company is positioned well for growth, with a Growth Style Score of B and a projected year-over-year earnings growth of 19.6% for the current fiscal year [12] - Recent analyst revisions have increased the earnings estimate for fiscal 2026 by $0.11 to $3.73 per share, alongside an average earnings surprise of +12.4% [12]

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors about its financial health and growth prospects, leading to a significant drop in stock price [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1][2]. - The allegations center around claims that Centene and its executives provided an overly optimistic view of the company's financial situation, particularly regarding revenue outlook and enrollment rates [3][4]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, stating that market growth across 22 states, which accounts for 72% of its marketplace membership, was "lower than expected," leading to a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price fell by more than 40%, resulting in billions of dollars in lost shareholder value [5]. Group 3: Investigative Actions - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][6]. - The firm suggests that if the allegations are proven true, they indicate a disconnect between Centene's public statements and its actual performance metrics [6].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to a significant drop in its stock price, with allegations of misleading investors about the company's financial health and growth prospects during a specified class period [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1][2]. - Accusations include that Centene and its executives presented an overly optimistic view of the company's financial status, claiming reliable information about projected revenue and growth while actual metrics indicated lower enrollment and increased morbidity [3][4]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states, which account for 72% of its marketplace membership, was lower than expected, leading to a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price fell by over 40%, resulting in billions of dollars in lost shareholder value [5]. Group 3: Investigation and Response - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][6]. - The firm suggests that if the allegations are proven true, they indicate a disconnect between Centene's public statements and its internal performance metrics, potentially leaving investors at a loss [6].

Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call. Up ...

Core Insights - Oppenheimer & Co. Inc. has appointed Jon Hudson as Managing Director and Co-Head of its Healthcare Services Investment Banking team, reflecting the firm's commitment to expanding its capabilities in the healthcare sector [1][2] - Hudson brings over 25 years of experience in the healthcare industry, focusing on M&A advisory and capital markets, particularly in provider and physician services, as well as the payor landscape [2][3] - The appointment is seen as a strategic move to enhance Oppenheimer's healthcare investment banking team, benefiting clients through Hudson's extensive expertise [4] Company Overview - Oppenheimer & Co. Inc. is a principal subsidiary of Oppenheimer Holdings Inc. and provides a full range of wealth management, securities brokerage, and investment banking services to high net-worth individuals, families, corporate executives, local governments, businesses, and institutions [4]

Investment Rating - The report maintains a "Buy" rating for Asymchem, Kangji Medical, Weigao, Angelalign, and Hygeia, while Tigermed, WuXi XDC, WuXi Biologics, and Frontage are rated as "Neutral" [11][15][18][27][36]. Core Insights - The report highlights a recovery in the healthcare sector, particularly in the CDMO segment, with expectations for earnings resilience driven by new order growth and demand from both US and EU markets, as well as from Chinese biotech licensing [2][3]. - The Medtech sector is anticipated to see clearer recovery in the second half of 2025, supported by normalized hospital activity and new product contributions [3]. - The report emphasizes the importance of monitoring pricing competition and consumption recovery signals in the services sector, particularly in consumer-related categories [4]. Summary by Sections CRO/CDMO - Earnings are expected to remain resilient, especially for companies with exposure to late-stage development and manufacturing projects [2]. - Key investor focus areas include new order growth, client behavior shifts amid policy uncertainties, and pricing and margin recovery [2][13]. - EPS estimates have been revised upward by an average of 1.3% to 1.4% for 2025-2027, with target prices adjusted by an average of 4% [1]. Medtech - Recovery is expected to materialize more clearly in the second half of 2025, with key areas to watch including the pace of VBP rollout and surgical volume trends [3]. - Companies like Weigao and Kangji are ramping up new product launches and global expansions, despite some tariff-related uncertainties [3]. Services - Reimbursement control and DRG/DIP pressure are likely to persist, impacting pricing and volumes [4]. - The report notes a cautious outlook for M&A activity, with companies like Hygeia becoming more positive while others remain cautious [9]. Financial Estimates - The report provides detailed financial estimates for various companies, indicating expected sales growth and net income projections for FY25 and beyond [14][19]. - For instance, WuXi Apptec is projected to achieve a revenue growth of 10-15% for FY25, while Asymchem anticipates double-digit revenue growth alongside margin improvements [19]. Target Price Changes - Target prices for several companies have been adjusted, with Asymchem's target price increased to HK$85.5, reflecting a 13% change [11][15]. - WuXi Biologics' target price is set at HK$25.6, based on a 12-month forward P/E of 22x [15][31]. Backlog and Order Trajectory - The report includes a detailed analysis of backlog and new order trajectories for key players in the CRO/CDMO space, indicating significant year-on-year growth in sales and backlog for companies like WuXi Apptec and WuXi Biologics [17].

Core Viewpoint - The Centene class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, leading to significant financial losses for shareholders [4][5]. Company Overview - Centene Corporation is a healthcare enterprise that provides integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Allegations of the Lawsuit - The lawsuit claims that Centene created a false impression of reliable revenue projections and growth while overstating enrollment rates and underreporting morbidity [4]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than expected, which led to a reduction in its guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price fell by more than 40% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Centene securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].